Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
25%(2 trials)

Phase Distribution

Ph phase_1
1
10%
Ph phase_2
3
30%
Ph phase_3
2
20%
Ph phase_4
2
20%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 32 (25.0%)
Phase 42 (25.0%)

Trials by Status

completed880%
withdrawn220%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT02937285Phase 3

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis

Completed
NCT00037115Phase 4

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Withdrawn
NCT00037102Phase 4

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

Completed
NCT01714089Phase 2

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Withdrawn
NCT01142453

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Completed
NCT00211887Phase 3

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

Completed
NCT01142518

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

Completed
NCT01071083Phase 2

Treatment Interruption of Natalizumab

Completed
NCT01863069Phase 1

Avonex®: Safety, Blood Levels and Effects

Completed
NCT01126177Phase 2

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10